Is HOMA-IR still used in clinical practice by consultants instead of the oral glucose tolerance test (OGTT)?

HOMA-IR Should NOT Replace OGTT in Clinical Practice

HOMA-IR has insufficient diagnostic performance to replace the oral glucose tolerance test (OGTT) for detecting dysglycemia and should not be used as a substitute by consultants in clinical practice 1. While HOMA-IR offers convenience, the OGTT remains the gold standard for diagnosing glucose intolerance and should still be prioritized despite its practical drawbacks.

Why OGTT Remains the Standard

The 2018 American Diabetes Association guidelines clearly establish that OGTT (75-g glucose load with 2-hour plasma glucose measurement) is one of three equally appropriate diagnostic tests for diabetes, alongside fasting plasma glucose and A1C 2. Notably, these guidelines make no mention of HOMA-IR as a diagnostic tool, which is telling about its clinical utility.

The most compelling recent evidence comes from the 2022 EUROASPIRE V study of 3,534 patients with coronary artery disease. This large-scale investigation found that HOMA-IR, HOMA2-ins, and HOMA2-Cpep all had low sensitivity and specificity for detecting dysglycemia when compared to OGTT 1. Among patients where 41% had dysglycemia, these insulin resistance indices failed to adequately identify affected individuals.

Where HOMA-IR Actually Fits

HOMA-IR does have legitimate but limited roles:

• Research settings: Acceptable for epidemiologic studies where the euglycemic clamp is impractical 3
• Clinical context assessment: May help estimate the relative contributions of insulin resistance versus insulinopenia in known type 2 diabetics 3
• Screening adjunct with risk factors: In specific populations (obese adolescents with acanthosis nigricans, pregnant women with risk factors), HOMA-IR may prompt earlier OGTT testing 4, 5

Critical Limitations of HOMA-IR

Several factors make HOMA-IR unreliable as a standalone diagnostic tool:

1. Population-specific variability: Reference ranges vary significantly by sex, age, BMI, and ethnicity, requiring population-specific cutoffs 6
2. Poor correlation with OGTT: While HOMA-IR correlates well with BMI and waist circumference, this doesn't translate to accurate dysglycemia detection 1
3. Misses isolated impaired glucose tolerance: HOMA-IR can be normal while OGTT reveals significant glucose intolerance 4

The Clinical Algorithm

When evaluating for dysglycemia:

1. First-line testing: Use OGTT, fasting plasma glucose, or A1C per ADA guidelines 2
2. Consider HOMA-IR only as supplementary information in patients with established diabetes to assess insulin resistance severity
3. If HOMA-IR is elevated in a screening context, confirm with OGTT—do not diagnose based on HOMA-IR alone
4. In high-risk populations (obese adolescents with acanthosis nigricans, family history of diabetes, hepatic steatosis), perform OGTT even if HOMA-IR is normal 4

Common Pitfalls to Avoid

• Don't assume normal HOMA-IR excludes dysglycemia: Up to 63% of obese adolescents with normal HOMA-IR had insulin resistance on OGTT 4
• Don't use universal cutoffs: HOMA-IR thresholds must be adjusted for age, sex, and BMI 6
• Don't substitute convenience for accuracy: While HOMA-IR requires only fasting samples, this convenience comes at the cost of diagnostic accuracy 1

The evidence is clear: OGTT should remain the preferred test when dysglycemia diagnosis is the clinical question. HOMA-IR serves as a research tool and clinical context marker, not a replacement for proper glucose tolerance testing.